Fingerprint
Dive into the research topics where Thomas J Flotte is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 9 Finished
-
Pathology Research Shared Resource
Flotte, T. J. (PI) & Flotte, T. T. J. (PI)
3/1/21 → 2/29/24
Project: Research project
-
-
-
Cellular Responses to Localized Oxidative Stress
Held, K. (PI), Flotte, T. J. (CoPI), Liber, H. L. (CoPI) & Redmond, R. W. (CoPI)
9/1/04 → 7/31/10
Project: Research project
-
-
Accuracy of PET–CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment
Stoff, R., Yalon, M., Thorpe, M. P., Flotte, T. J., Block, M. S. & Hieken, T. J., Nov 2025, In: Annals of surgical oncology. 32, 12, p. 8946-8957 12 p.Research output: Contribution to journal › Article › peer-review
-
Democratizing Artificial Intelligence in Anatomic Pathology
Flotte, T. J., Derauf, S. A., Byrd, R. K., Kroneman, T. N., Bell, D. A., Stetzik, L., Lee, S. Y., Samiei, A., Hart, S. N., Garcia, J. J., Beamer, G. & Westerling-Bui, T., Jan 2025, In: Archives of Pathology and Laboratory Medicine. 149, 1, p. 55-59 5 p.Research output: Contribution to journal › Article › peer-review
Open Access -
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
Hieken, T. J., Zahrieh, D., Flotte, T. J., Dronca, R. S., Domingo-Musibay, E., Nelson, G. D., Strand, C. A., Kottschade, L. A., Montane, H. N., Piltin, M. A., Chen, R., McWilliams, R. R., Jakub, J. W., Khariwala, S. S., Dudek, A. Z., Johnson, J. E., Markovic, S. N., Dimou, A., Tasche, K. K. & Block, M. S., Sep 9 2025, In: European Journal of Cancer. 227, 115688.Research output: Contribution to journal › Article › peer-review
Open Access -
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: Outcomes and the impact of the microbiome from the NeoACTIVATE trial
Block, M. S., Nelson, G. D., Chen, J., Johnson, S., Yang, L., Flotte, T. J., Grewal, E. P., McWilliams, R. R., Kottschade, L. A., Domingo-Musibay, E., Markovic, S. N., Dimou, A., Montane, H. N., Piltin, M. A., Price, D. L., Khariwala, S. S., Hui, J. Y. C., Erskine, C. L., Strand, C. A. & Zahrieh, D. & 2 others, , Apr 15 2025, In: Journal for ImmunoTherapy of Cancer. 13, 4, e011706.Research output: Contribution to journal › Article › peer-review
Open Access -
Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy
Tanabe, K. K., Zahrieh, D., Strand, C. A., Hoshida, Y., Flotte, T. J., Della'Zanna, G., Umar, A., Chavin, K. D., Cleary, S., Kubota, N., Llovet, J. M., Patel, T., Siegel, C. & Limburg, P. J., Jan 2024, In: Gastro Hep Advances. 3, 3, p. 426-439 14 p.Research output: Contribution to journal › Article › peer-review
Open Access